Results 181 to 190 of about 79,283 (266)

Global trends and emerging insights in BRAF and MEK inhibitor resistance in melanoma: a bibliometric analysis. [PDF]

Front Mol Biosci
Bai J, Wan Z, Zhou W, Wang L, Lou W, Zhang Y, Jin H.   +6 more
europepmc   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, Volume 159, Issue 7, Page 1735-1749, 1 October 2026.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

The MEK inhibitor trametinib is effective in inhibiting the growth of canine oral squamous cell carcinoma. [PDF]

Sci Rep
Katt WP, Balkman CE, Butler SD, Byron M, Carney PC, Todd-Donato AB, Drozd ME, Duhamel GE, Evans JM, Fiani N, Ford JC, Grenier JK, Hayward JJ, Heikinheimo K, Hume KR, Moore ES, Puri R, Sylvester SR, Warshaw SL, Webb SM, White AC, Wright AL, Cerione RA, Peralta S.   +23 more
europepmc   +1 more source

Real‐World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond

International Journal of Cancer, Volume 159, Issue 7, Page 1780-1787, 1 October 2026.
Progression after anti‐PD‐1‐based therapy is a predominant scenario in metastatic melanoma. However, real‐world data informing treatment of metastatic melanoma in later lines remains scarce. This retrospective nationwide, population‐based cohort study shows in a real‐world setting that nivolumab plus ipilimumab can induce durable responses beyond the ...
Yago Garitaonaindia, Søren Kjær Petersen, Louise M. Guldbrandt, Troels H. Borch, Christina H. Ruhlmann, Rasmus Blechingberg Friis, Adam A. Luczak, Lars Bastholt, Henrik Schmidt, Inge Marie Svane, Eva Ellebaek, Marco Donia   +11 more
wiley   +1 more source

Genomic profiling of Mexican patients with B‐cell precursor acute lymphoblastic leukemia reveals clinically significant somatic and potential germline variants

The Journal of Pathology: Clinical Research, Volume 12, Issue 5, September 2026.
Abstract B‐cell precursor acute lymphoblastic leukemia (preB‐ALL) is characterized by pathogenic variants currently used in precision oncology. However, the mutational landscape of Mexican children with preB‐ALL has not yet been thoroughly explored and defined in terms of the clinical significance.
Daniel Martínez Anaya, María del Rocío Juárez‐Velázquez, Ulises Juárez Figueroa, Michael Dean, Consuelo Salas Labadía, Marian Valladares Coyotecatl, Adriana Reyes León, Norma López Santiago, Luis Juárez Villegas, Marta Zapata Tarrés, Patricia Pérez‐Vera   +10 more
wiley   +1 more source

Elevated lactate dehydrogenase in adjuvant BRAF and MEK inhibitor therapy does not have diagnostic significance in detecting melanoma recurrence. [PDF]

Contemp Oncol (Pozn)
Galus Ł, Tusień-Małecka D, Mackiewicz J.   +2 more
europepmc   +1 more source

Resolution of Refractory Multifocal Atrial Tachycardia in Costello Syndrome Using Trametinib: A Case Supporting MEK Inhibitors as Targeted, Specific Antiarrhythmic

American Journal of Medical Genetics Part A, Volume 200, Issue 9, Page 2151-2156, September 2026.
ABSTRACT Arrhythmias affect approximately half of patients with Costello syndrome (CS, OMIM # 218040), with non‐reentrant atrial tachycardia being the most common. This case describes an infant with Costello syndrome carrying the pathogenic HRAS c.34G>A (p.G12S) variant who developed early‐onset, drug‐refractory multifocal atrial tachycardia (MAT ...
Vanina Taliercio, Annabelle Wilcox, Stacey Cole, Josue Flores Daboub, José E. Morales Moreno, Kasey G. Andrews, S. Yukiko Asaki, Thomas A. Pilcher, Martin Tristani‐Firouzi, Mary C. Niu, David Viskochil, Benjamin Hammond   +11 more
wiley   +1 more source

Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study. [PDF]

Cancer Immunol Immunother
Beckmann M, Schlüter J, Erdmann M, Kramer R, Cunningham S, Hackstein H, Zimmermann R, Heinzerling L.   +7 more
europepmc   +1 more source

Vitamin C and MEK Inhibitor PD0325901 Synergistically Promote Oligodendrocytes Generation by Promoting DNA Demethylation. [PDF]

Molecules
Ren X, Yang Y, Wang M, Yuan Q, Suo N, Xie X.   +5 more
europepmc   +1 more source

Langerhans Cell Histiocytosis in Adults: A Canadian Multicenter Case Series

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Langerhans cell histiocytosis (LCH) is a rare clonal myeloid neoplasm. Canadian data on clinical characteristics, molecular profile, and treatment outcomes is limited. This study aims to report the initial experience of a Canadian rare diseases program, reflecting “real‐world” diagnostic pathways, referral patterns, and treatment heterogeneity
Stephanie Quon, Yaswanta Gummadi, Ibrahim Elsharawi, Jessica Dobson, Mariam Goubran, Ryan J. Stubbins, Eli L. Diamond, Luke Y. C. Chen   +7 more
wiley   +1 more source